MGC Pharmaceuticals (ASX:MXC) share price climbs on study approval

The Israeli Ministry of Health has approved a dosing study of a drug candidate. Here are the details

| More on:
A group of three scientists talking excitedly while working in a lab on a diabetes test developed by Proteomics International Laboratories which is an ASX share tipped to explode by Alto Capital

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The MGC Pharmaceuticals Ltd (ASX: MXC) share price is shooting higher and is currently up around 2% at 4.9 cents. Earlier in the day it was up to 5.1 cents, a gain of around 6% on the previous closing price.

MGC shares have been in the green all day after the biopharmaceuticals and phytomedicine company announced a key update regarding its drug candidate CimetrA.

Here are the details.

What did MGC Pharmaceuticals announce?

MGC said the Israeli Ministry of Health had approved a dosing study of CimetrA, indicated in the potential treatment of Covid-19. Today's announcement appears to have impressed investors, pushing the MGC Pharmaceuticals share price higher.

For reference, CimetrA is formulated from naturally derived anti-inflammatories found in the plants Curcumin and Boswellia (also known as Indian frankincense).

A dosing study is a necessary step in a drug's approval process. It is used to determine the most effective amount of active ingredient required to achieve a desired response, without causing any adverse side effects.

The aim is to identify a label's "therapeutic dose" alongside a wider safety profile, in preparation for registration and sale to the public.

As such, MGC's latest study will "further examine the anti-inflammatory and immune-modulatory effects of CimetrA".

It will recruit 240 patients across a number of jurisdictions, including Israel, South Africa, the US, and Russia. After which, results will be submitted to the health authorities of each country.

Interpretation of the results will then be used to determine the "most effective dosage of CimetrA for treating symptoms of Covid-19". This includes a rare but serious complication known as a 'cytokine storm'.

Cytokines are markers in the body that are critical in regulating the immune system. Covid-19 can cause them to be released in overwhelming abundance — a cytokine storm — which is detrimental to the body's tissues.

Previous studies MGC has undertaken support CimetrA's use as an immune system modulator that is effective in preventing and treating cytokine storms.

This appears significant, as cytokine storms are believed to be the main cause of death in Covid-19 patients.

What is management saying?

Speaking on the announcement possibly driving the MGC Pharmaceuticals share price, co-founder and managing director Roby Zomer said:

This latest dosage study is the latest step as we move closer to being in a position to apply for marketing authorisation for CimetrA™ in territories across the globe.

We believe that CimetrA will prove to be a vitally important drug in the treatment of COVID-19 going forward, and look forward to sharing the results of the study in due course, along with further steps towards providing COVID-19 patients and governments across the world a cost-effective treatment to fast-track patient recovery and minimise the massive cost burden of long-term hospitalisation.

MGC Pharmaceuticals share price snapshot

The MGC Pharmaceuticals share price has been an outsized winner this year to date, having climbed almost 100%.

It has also gained 122% over the past 12 months. That's well ahead of the benchmark S&P/ASX 200 index (ASX: XJO)'s return of around 25% in that time.

The author Zach Bristow has no positions in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

ASX healthcare stock surges 11% on 'incredibly valuable' FDA news

Some big news is getting investors excited on Tuesday. What's happening?

Read more »

A man thinks very carefully about his money and investments.
Healthcare Shares

How much could $10,000 invested in CSL shares be worth next year?

Do analysts think it would be worth sinking money into this top stock?

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

This ASX All Ords stock is rocketing 20% after accepting a takeover offer

These two diagnostics companies are planning to merge their operations.

Read more »

A man sleeps in a bed with white sheets while holding a teddy bear and a smile on his face.
Healthcare Shares

Buy the ASX 200 healthcare stock with 'decades of growth ahead'

This healthcare giant is well positioned for growth, experts say.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Telix Pharmaceuticals share price sinks on unexpected Nasdaq news

ASX 200 investors are bidding down the Telix Pharmaceuticals share price today. But why?

Read more »

Health workers shake hands and congratulate each other on good news.
Healthcare Shares

This ASX 200 healthcare stock is up 48% in a year, but one director is still buying!

A director of this ASX 200 healthcare company has just lifted his personal stake by 50%.

Read more »

A man and woman in an office look at a laptop and discuss investing, budget strategies or other financial concepts
Healthcare Shares

Why this broker just upgraded Telix shares to a buy rating

Bell Potter thinks a recent pullback has created a buying opportunity.

Read more »

A female scientist sits at her desk looking stressed out while working in an AnteoTech lab.
Healthcare Shares

Sigma share price dives 6% on Chemist Warehouse merger hurdle

The proposed merger faces ACCC concerns.

Read more »